18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

Naghmehossadat Eshghi; Tamara F. Lundeen; Lea Mackinnon; Ryan Avery; Phillip H Kuo

doi:10.1097/RLU.0000000000002051

18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

Naghmehossadat Eshghi, Tamara F. Lundeen, Lea Mackinnon, Ryan Avery, Phillip H Kuo

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

Original language	English (US)
Pages (from-to)	e142-e144
Journal	Clinical nuclear medicine
Volume	43
Issue number	5
DOIs	https://doi.org/10.1097/RLU.0000000000002051
State	Published - May 1 2018

Keywords

FDG PET/CT
Merkel cell carcinoma
avelumab
immunotherapy

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000002051

Cite this

@article{5ca67ded986a423d8dbcc581cc09ac20,

title = "18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab",

abstract = "An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.",

keywords = "FDG PET/CT, Merkel cell carcinoma, avelumab, immunotherapy",

author = "Naghmehossadat Eshghi and Lundeen, {Tamara F.} and Lea Mackinnon and Ryan Avery and Kuo, {Phillip H}",

year = "2018",

month = may,

day = "1",

doi = "10.1097/RLU.0000000000002051",

language = "English (US)",

volume = "43",

pages = "e142--e144",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

TY - JOUR

T1 - 18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

AU - Eshghi, Naghmehossadat

AU - Lundeen, Tamara F.

AU - Mackinnon, Lea

AU - Avery, Ryan

AU - Kuo, Phillip H

PY - 2018/5/1

Y1 - 2018/5/1

N2 - An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

AB - An 85-year-old man with stage IIIA Merkel cell carcinoma of the left arm was initially treated with local excision and axillary node dissection followed by radiation therapy. Eight months after surgery, whole-body FDG PET/CT demonstrated intensely hypermetabolic hepatic metastases and abdominal lymphadenopathy. Given his age and comorbidities, he was considered a poor candidate for chemotherapy, and therefore the novel programmed cell death ligand 1 inhibitor avelumab was initiated. FDG PET/CT after 4 cycles showed complete resolution of hepatic and nodal metastases. Whole-body FDG PET/CT can be used for monitoring response of multisystem metastases from Merkel cell carcinoma to active immunotherapy.

KW - FDG PET/CT

KW - Merkel cell carcinoma

KW - avelumab

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85045696297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045696297&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002051

DO - 10.1097/RLU.0000000000002051

M3 - Article

C2 - 29538029

AN - SCOPUS:85045696297

SN - 0363-9762

VL - 43

SP - e142-e144

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 5

ER -

18F-FDG PET/CT for Monitoring Response of Merkel Cell Carcinoma to the Novel Programmed Cell Death Ligand 1 Inhibitor Avelumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this